BioCentury
ARTICLE | Clinical News

CF102 regulatory update

September 21, 2015 7:00 AM UTC

FDA granted Fast Track designation to Can-Fite’s CF102 as a second-line treatment for hepatocellular carcinoma (HCC). The nucleoside adenosine A3 receptor (ADORA3) agonist is in Phase II testing to t...